3016307-75-5
Chemical Structure
PhosTAC7
Synonym(s): OGTAC-3
- CAS No.: 3016307-75-5
- Formula:C58H87ClN2O17
- Molecular Weight:1119.77
IUPAC Name: (R)-1-(3-((30-chloro-2-oxo-6,9,12,15,18,21,24-heptaoxa-3-azatriacontyl)oxy)phenyl)-3-(3,4-dimethoxyphenyl)propyl (S)-1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate
InChIKey: RPIBISHYKGHEDG-YGENRYQBSA-N
SMILES: CC[C@@H](C1=CC(OC)=C(C(OC)=C1)OC)C(N2CCCC[C@H]2C(O[C@@H](C3=CC(OCC(NCCOCCOCCOCCOCCOCCOCCOCCCCCCCl)=O)=CC=C3)CCC4=CC(OC)=C(C=C4)OC)=O)=O
Biological Activity: PhosTAC7 is a heterobifunctional molecule named as a Phosphorylation Targeting Chimera (PhosTAC). PhosTAC7 can dephosphorylate the PDCD4 protein, FOXO3a protein, and tau protein by recruiting serine/threonine protein phosphatase 2A (PP2A). PhosTAC7 offers the advantage of selectively modulating the phosphorylation state of individual target proteins, making it a promising tool for research in cancer and tau protein-related neurodegenerative diseases (Alzheimer's disease)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PhosTAC7 | 99.23% | PhosTAC7 is a heterobifunctional molecule named as a Phosphorylation Targeting Chimera (PhosTAC). PhosTAC7 can dephosphorylate the PDCD4 protein, FOXO3a protein, and tau protein by recruiting serine/threonine protein phosphatase 2A (PP2A). PhosTAC7 offers the advantage of selectively modulating the phosphorylation state of individual target proteins, making it a promising tool for research in cancer and tau protein-related neurodegenerative diseases (Alzheimer's disease). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Chen PH, et al. Modulation of Phosphoprotein Activity by Phosphorylation Targeting Chimeras (PhosTACs). ACS Chem. Biol. 2021 Nov 15.
- [2]. Hu Z, et al. Targeted Dephosphorylation of Tau by Phosphorylation Targeting Chimeras (PhosTACs) as a Therapeutic Modality. J Am Chem Soc. 2023 Feb 8. [Content Brief]
Keywords
